These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 23744810)

  • 1. Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation.
    McGonigal KH; Bajjoka IE; Abouljoud MS
    Pharmacotherapy; 2013 Sep; 33(9):e170-6. PubMed ID: 23744810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.
    Stravitz RT; Shiffman ML; Kimmel M; Puri P; Luketic VA; Sterling RK; Sanyal AJ; Cotterell AH; Posner MP; Fisher RA
    Liver Int; 2012 Aug; 32(7):1138-45. PubMed ID: 22348467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
    Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
    Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
    Berg T; Zoulim F; Moeller B; Trinh H; Marcellin P; Chan S; Kitrinos KM; Dinh P; Flaherty JF; McHutchison JG; Manns M
    J Hepatol; 2014 Apr; 60(4):715-22. PubMed ID: 24295873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
    Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
    Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.
    Teperman LW; Poordad F; Bzowej N; Martin P; Pungpapong S; Schiano T; Flaherty J; Dinh P; Rossi S; Subramanian GM; Spivey J
    Liver Transpl; 2013 Jun; 19(6):594-601. PubMed ID: 23447407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
    Santos SA; Uriel AJ; Park JS; Lucas J; Carriero D; Jaffe D; Dieterich DT
    Eur J Gastroenterol Hepatol; 2006 Dec; 18(12):1247-53. PubMed ID: 17099372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
    Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
    Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
    Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
    Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B and liver transplantation: 2008 update.
    Beckebaum S; Sotiropoulos GC; Gerken G; Cicinnati VR
    Rev Med Virol; 2009 Jan; 19(1):7-29. PubMed ID: 18816503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
    Schiff E; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann H; Samuel D; Zeuzem S; Villeneuve JP; Arterburn S; Borroto-Esoda K; Brosgart C; Chuck S;
    Liver Transpl; 2007 Mar; 13(3):349-60. PubMed ID: 17326221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
    Berg T; Marcellin P; Zoulim F; Moller B; Trinh H; Chan S; Suarez E; Lavocat F; Snow-Lampart A; Frederick D; Sorbel J; Borroto-Esoda K; Oldach D; Rousseau F
    Gastroenterology; 2010 Oct; 139(4):1207-17. PubMed ID: 20600025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.